1
Toufike Kanouni
Qing Dong, Toufike Kanouni, Michael B Wallace: MAPK/ERK kinase inhibitors. Takeda Pharmaceutical Company, David M Stemerick, Mitchell R Brustein, September 20, 2011: US08022057 (1 worldwide citation)

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


2
Toufike Kanouni
Qing Dong, Toufike Kanouni, John David Lawson, Michael B Wallace: Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK. Takeda Pharmaceutical Company, Matthew J Russo, David M Stemerick, April 16, 2013: US08420816

Disclosed are JAK inhibitors of formula I where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the ...


3
Toufike Kanouni
Qing Dong, Xianchang Gong, Stephen W Kaldor, Toufike Kanouni, Nicholas Scorah, Michael B Wallace, Feng Zhou: MAPK/ERK KINASE INHIBITORS. TAKEDA PHARMACEUTICAL COMPANY, TAKEDA SAN DIEGO, May 27, 2010: US20100130518-A1

Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of usin ...


4
Toufike Kanouni
Qing Dong, Xianchang Gong, Stephen W Kaldor, Toufike Kanouni, Nicholas Scorah, Michael B Wallace, Feng Zhou: Mapk/erk kinase inhibitors. Takeda San Diego, October 16, 2008: US20080255160-A1

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


5
Toufike Kanouni
Pierre Yves Bounaud, Stephanie A Hopkins, Elizabeth Anne Jefferson, Mark E Wilson, Melissa S Wong, Toufike Kanouni: Pyrazolothiazole Protein Kinase Modulators. SGX Pharmaceuticals, Townsend And Townsend And Crew, July 26, 2007: US20070173488-A1

The present invention provides pyrazolothiazole kinase modulators, methods of treating certain disease states, such as cancer, and pharmaceutical composition thereof.


6
Toufike Kanouni
Qing Dong, Toufike Kanouni, John David Lawson, Michael B Wallace: Dihydropyrrolonaphtyridinone compounds as inhibitors of jak. Takeda Pharmaceutical Company, June 9, 2011: US20110136780-A1

Disclosed are JAK inhibitors of formula I where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the ...


7
Toufike Kanouni
MarK Adams, Qing Dong, Toufike Kanouni, Stephen W Kaldor, Nicholas Scorah, Michael B Wallace: Mapk/erk kinase inhibitors. Takeda Pharmaceutical Company, Takeda San Diego, May 14, 2009: US20090124595-A1

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


8
Young K Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace: Histone demethylase inhibitors. Quanticel Pharmaceuticals, Wilson Sonsini Goodrich & Rosati, February 10, 2015: US08952151 (6 worldwide citation)

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are ...


9
Young K Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace: Histone demethylase inhibitors. QUANTICEL PHARMACEUTICALS, Wilson Sonsini Goodrich & Rosati, July 21, 2015: US09085534 (3 worldwide citation)

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are ...


10
Young K Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace: Histone demethylase inhibitors. Celgene Quanticel Research, Wiley Rein, September 20, 2016: US09447045 (2 worldwide citation)

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are ...